DE60011761D1 - Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen - Google Patents

Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen

Info

Publication number
DE60011761D1
DE60011761D1 DE60011761T DE60011761T DE60011761D1 DE 60011761 D1 DE60011761 D1 DE 60011761D1 DE 60011761 T DE60011761 T DE 60011761T DE 60011761 T DE60011761 T DE 60011761T DE 60011761 D1 DE60011761 D1 DE 60011761D1
Authority
DE
Germany
Prior art keywords
arpe
cell line
cells
administrating
platform cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011761T
Other languages
English (en)
Other versions
DE60011761T2 (de
Inventor
Weng Tao
H Rein
J Dean
F Stabila
B Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech USA Inc
Original Assignee
Neurotech SA France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech SA France filed Critical Neurotech SA France
Application granted granted Critical
Publication of DE60011761D1 publication Critical patent/DE60011761D1/de
Publication of DE60011761T2 publication Critical patent/DE60011761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE60011761T 1999-04-06 2000-04-06 Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen Expired - Lifetime DE60011761T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US543119 1990-06-22
US12792699P 1999-04-06 1999-04-06
US127926P 1999-04-06
US09/543,119 US6361771B1 (en) 1999-04-06 2000-04-05 ARPE-19 as a platform cell line for encapsulated cell-based delivery
PCT/US2000/009150 WO2000060051A2 (en) 1999-04-06 2000-04-06 Arpe-19 as a platform cell line for encapsulated cell-based delivery

Publications (2)

Publication Number Publication Date
DE60011761D1 true DE60011761D1 (de) 2004-07-29
DE60011761T2 DE60011761T2 (de) 2005-08-04

Family

ID=26826092

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011761T Expired - Lifetime DE60011761T2 (de) 1999-04-06 2000-04-06 Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen

Country Status (12)

Country Link
US (2) US6361771B1 (de)
EP (1) EP1171573B1 (de)
JP (2) JP4954374B2 (de)
AT (1) ATE269715T1 (de)
AU (1) AU773387B2 (de)
BR (1) BR0009562A (de)
CA (1) CA2365532C (de)
DE (1) DE60011761T2 (de)
DK (1) DK1171573T3 (de)
ES (1) ES2219335T3 (de)
NO (1) NO20014856D0 (de)
WO (1) WO2000060051A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2003033016A1 (en) * 2001-10-16 2003-04-24 Jenny Phipps Use of neurotrophic factors for treating neurodegenerative diseases and cancer
US20040005302A1 (en) * 2002-04-30 2004-01-08 Gonzalo Hortelano Encapsulated cells to elicit immune responses
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
DE602004021648D1 (de) 2003-04-18 2009-07-30 Biogen Idec Inc Polymerkonjugiertes glycosiliertes Neublastin
RU2005138368A (ru) * 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7927599B2 (en) * 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8257963B2 (en) * 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
DE602005022457D1 (de) * 2004-08-19 2010-09-02 Biogen Idec Inc Neublastin-varianten
ES2349043T3 (es) * 2004-08-19 2010-12-22 Biogen Idec Ma Inc. Variantes de neublastina.
US8088567B2 (en) * 2005-04-01 2012-01-03 Nsgene A/S Human immortalised neural precursor cell line
CA2609000C (en) * 2005-05-17 2015-01-13 Nsgene A/S An implantable therapy system for treating a living being with an active factor
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
JP2009513584A (ja) * 2005-10-28 2009-04-02 エヌエスゲーネ・アクティーゼルスカブ Gdnfの送達のための移植可能な生体適合性免疫隔離ビヒクル
AU2006332971B2 (en) * 2005-12-30 2013-03-07 Neurotech Usa, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
ES2476253T3 (es) * 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
US8075537B2 (en) * 2008-08-15 2011-12-13 Oxyband Technologies, Inc. Multiple cell therapeutic diffusion device
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
AU2010206374B2 (en) * 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
EP2421981B1 (de) * 2009-04-23 2013-08-14 Neurotech USA, Inc. Zelllinien zur produktion von prostaglandin-f2-alpha (pgf2a) und verwendungen davon
WO2011044216A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US8808687B2 (en) 2010-07-12 2014-08-19 Mark Humayun Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
KR20140091651A (ko) 2010-12-02 2014-07-22 뉴로테크 유에스에이, 인코포레이티드. 항-혈관 신생 항체-스캐폴드 및 가용성 수용체를 분비하는 세포주 및 이의 용도
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
MX354516B (es) 2011-10-27 2018-03-08 Wellstat Ophthalmics Corp Vectores que codifican el factor de viabilidad de conos derivado de bastones.
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
WO2013181424A1 (en) 2012-05-30 2013-12-05 Neurotech Usa, Inc. Cryopreserved implantable cell culture devices and uses thereof
US20160123960A1 (en) * 2013-06-10 2016-05-05 Millennium Pharmaceuticals, Inc. Method for preparing three-dimensional, organotypic cell cultures and uses thereof
CA2922483A1 (en) * 2013-09-11 2015-03-19 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
FR3014316B1 (fr) 2013-12-10 2017-01-20 Defymed Organe bioartificiel
EP3188712A1 (de) 2014-09-04 2017-07-12 Kemijski Institut Zellbasierte vorrichtung zur lokalen behandlung mit therapeutischem protein
EP3302524B1 (de) * 2015-05-27 2020-09-23 Neurotech USA, Inc. Verwendung von eingekapselter zelltherapie zur behandlung von glaukom
CA3156956A1 (en) 2019-11-01 2021-05-06 Neurotech Usa, Inc. System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device
CN115697300A (zh) 2020-04-09 2023-02-03 帝梵麦德公司 用于医疗装置的膜
EP3892259A1 (de) 2020-04-09 2021-10-13 Defymed Membranen für medizinische vorrichtungen
WO2022011081A1 (en) 2020-07-09 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell lines that produce human retinoschisin proteins and uses thereof
EP4333872A1 (de) 2021-05-06 2024-03-13 Hoba Therapeutics ApS Vorbeugung und behandlung von chemotherapie-induzierten neuropathischen schmerzen
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
FR2681609B1 (fr) 1991-09-24 1994-12-30 Centre Nat Rech Scient Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.
WO1994001139A1 (en) 1992-07-13 1994-01-20 Baylor College Of Medicine Targeting somatic gene therapy to joints
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
AU688776B2 (en) 1993-06-23 1998-03-19 Brown University Research Foundation Method and apparatus for sealing implantable, membrane encapsulation devices
JP4098355B2 (ja) 1993-08-12 2008-06-11 ニューロテック ユーエスエー, インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6020192A (en) * 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US5998598A (en) 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery

Also Published As

Publication number Publication date
ES2219335T3 (es) 2004-12-01
US7115257B1 (en) 2006-10-03
DK1171573T3 (da) 2004-09-27
CA2365532A1 (en) 2000-10-12
EP1171573B1 (de) 2004-06-23
BR0009562A (pt) 2007-05-29
WO2000060051A2 (en) 2000-10-12
ATE269715T1 (de) 2004-07-15
WO2000060051A3 (en) 2002-03-28
EP1171573A1 (de) 2002-01-16
CA2365532C (en) 2012-11-06
JP4954374B2 (ja) 2012-06-13
JP2003524621A (ja) 2003-08-19
AU4331900A (en) 2000-10-23
AU773387B2 (en) 2004-05-27
WO2000060051A8 (en) 2001-04-05
JP2011074079A (ja) 2011-04-14
DE60011761T2 (de) 2005-08-04
US6361771B1 (en) 2002-03-26
NO20014856D0 (no) 2001-10-05

Similar Documents

Publication Publication Date Title
DE60011761D1 (de) Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen
Jiang et al. Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages
Chae et al. Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin
Wong et al. Pullulan hydrogels improve mesenchymal stem cell delivery into high‐oxidative‐stress wounds
Kokoshis et al. Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan
Carrade et al. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions
FI95044B (fi) Uudet immobilisoidut biokatalysaattorit sekä niiden valmistus ja käyttö
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
AU2006201898A1 (en) Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
EP1553893A2 (de) Implantation von verkapseltem biologischem material zur behandlung von krankheiten
ATE284674T1 (de) Hybride matrizen und gemische davon
ATE446373T1 (de) Sequenz-spezifische dna-rekombination in eukaryotischen zellen
Matsushima et al. Bidirectional homing of Tregs between the skin and lymph nodes
WO2017024076A1 (en) Cell transplantation device
Slavin et al. Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation
CN101947312B (zh) 一种可直接皮肤外用的mPEG-SOD纳米乳及其制备方法
CN110114060A (zh) 具有杀菌作用的制剂
NO20000990D0 (no) Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>
Wee et al. Cell surface modification by activated polyethylene glycol prevents allosensitization after islet transplantation
CN104224839A (zh) 一种具有抗衰老功效的干细胞注射液及其制备方法
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
Bustos et al. Enzyme replacement therapy in porphyrias-III: Potential use of erythrocyte ghosts as carriers of δ-aminolaevulinate dehydratase
Sibuea et al. TNF-α and IL-10 as paracrine effect of encapsulated mesenchymal stem cells coating by platelet lysate
ATE336569T1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
CN1340342A (zh) 用哌啶类氮氧化物防治皮肤的氧化性损伤

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NEUROTECH S.A., PARIS, FR

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEUROTECH USA, INC. (N. D. GES. D. STAATES DEL, US